A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects

Phase 1 Active not recruiting 190 enrolled Qilu Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2106 versus Tremfye®（Guselkumab） in healthy subjects after a single dose.

Timeline

Start: 2025-11-10
Primary completion: 2026-04-12
Completion: 2026-08-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QL2106	Unknown	100 mg	Subcutaneous
Comparator	Tremfye®	Unknown	100 mg	Subcutaneous

Indications

No indication recorded.